Novavax Inc (NVAX)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$6.58
Buy
$6.61
$-0.12 (-1.79%)
Prices updated at 13 Dec 2025, 00:59 EST
| Prices minimum 15 mins delay
Prices in USD
Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 556m | 682m | |
| 213m | 479m | |
| -567m | -249m | |
| -101.82 | -36.49 | |
| -545m | -187m | |
| -487m | -108m | |
| Sales, General and administrative | 469m | 337m |
| Interest expenses | 14m | 20m |
| Provision for income taxes | 2m | 11m |
| Operating expenses | 779m | 728m |
| Income before taxes | -543m | -177m |
| Net income available to common shareholders | -545m | -187m |
| -5.41 | -1.23 | |
| Net interest income | -14m | -20m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -5.41 | -1.23 |
| Free cash flow per share | -8.0985 | -0.7851 |
| Book value/share | -4.8625 | -3.2816 |
| Debt equity ratio | - | - |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 1,144m | 1,129m |
| Current liabilities | 1,635m | 1,154m |
| Total capital | -549m | -454m |
| Total debt | 229m | 230m |
| Total equity | -717m | -624m |
| Total non current liabilities | - | - |
| Loans | 168m | 170m |
| Total assets | 1,797m | 1,560m |
| Total liabilities | - | - |
| Cash and cash equivalents | 569m | 530m |
| Common stock | 140m | 160m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 1,349m | 584m |
| Cash dividends paid | - | - |
| -773m | -102m | |
| Investments (gains) losses | -59m | -204m |
| 584m | 545m | |
| Net income | - | - |
| -714m | -87m | |
| -59m | -15m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
